Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Leap Therapeutics

Leap Therapeutics
2011 FOUNDED
PUBLIC STATUS
21-30 EMPLOYEES
LPTX STOCK SYMBOL
3 INVESTMENTS
$1.17 SHARE PRICE (As of Monday Closing)
Description

Leap Therapeutics Inc is a biopharmaceutical company. The company is acquiring and developing novel therapeutics at the leading edge of cancer biology. Its programs are monoclonal antibodies that target key cellular pathways that enable cancer to grow and spread and specific mechanisms that activate the body's immune system to identify and attack cancer. Leap has two clinical stage programs: DKN-01 and TRX518. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1, or DKK1, a protein that regulates important cell signaling pathways, known as the Wnt pathways. TRX518 is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor, or GITR, a receptor found on the surface of a wide range of immune cells.

Website
Formerly Known As
HealthCare Pharmaceuticals
Ownership Status
Publicly Held
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Stock Exchange
NAS
Primary Office
  • 47 Thorndike Street
  • Suite B1-1
  • Cambridge, MA 02141
  • United States

+1 (617) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Leap Therapeutics’s full profile, request a free trial.

Leap Therapeutics Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$1.09 - $6.74 $28.1M $1.22 -$1.15 314K 24M

Leap Therapeutics Financials Summary

In Thousands,
USD
TTM
30-Jun-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 20,941 20,609 62,886 23,629
Revenue 0 0 0
EBITDA (22,479) (23,497) (29,357) (24,376)
Net Income (22,121) (23,138) (29,727) (25,632)
Total Assets 20,137 19,074 29,062 6,457
Total Debt 1,399 3,448 11,862 30,274
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Leap Therapeutics Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Leap Therapeutics‘s full profile, request access.

Request full access to PitchBook

Leap Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is reserved for PitchBook Platform users. To explore Leap Therapeutics‘s full profile, request access.

Request full access to PitchBook
To view this company’s complete Cap Table, request access »

Leap Therapeutics Competitors (36)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Celgene Pending Transaction (M&A) Summit, NJ 0000 000.00 000000&0 000.00
00000000000 000000 Formerly VC-backed Abingdon, United Kingdom 000 00000 000000 - 000 00000
0000 000000 Formerly VC-backed Santa Monica, CA 000 00000 000000&0 00000
000000000 Private Equity-Backed Gaithersburg, MD 000.00 0000000 0000 000.00
0000000 Formerly VC-backed Cambridge, MA 00 00000 00000000000 00000
To view this company’s complete list of competitors, request access »

Leap Therapeutics Acquisitions (3)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000000 23-Jan-2017 000000000000000000 Biotechnology 00000000000 000000000 00.0
0000 21-Jan-2016 000000 00 000000 Drug Discovery 0000000 0000 00
HealthCare Pharmaceuticals 21-Jan-2016 Merger of Equals Biotechnology
To view this company’s complete investment and acquisition history, request access »

Leap Therapeutics Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Leap Therapeutics‘s full profile, request access.

Request full access to PitchBook

Leap Therapeutics Executive Team (5)

Name Title Board
Seat
Contact
Info
Christopher Mirabelli Ph.D Chief Executive Officer & Chairman
Douglas Onsi JD Chief Financial Officer & Chief Accounting Officer
Augustine Lawlor Chief Operating Officer
Jonathan Miller Associate Director, Business Development

1 Former Executive

You’re viewing 4 of 5 executives. Get the full list »

Leap Therapeutics Board Members (7)

Name Representing Role Since Contact
Info
Christopher Mirabelli Ph.D Leap Therapeutics Chief Executive Officer & Chairman 000 0000
James Cavanaugh Ph.D HealthCare Ventures Board Member 000 0000
John Littlechild HealthCare Ventures Board Member 000 0000
Joseph Loscalzo Ph.D Leap Therapeutics Board Member 000 0000
Nissim Mashiach MacroCure Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »